Home         Forums  

Go Back   Marrowforums > Treatments > Drugs and Drug Treatments
Register FAQ Search Today's Posts Mark Forums Read

Drugs and Drug Treatments ATG, Cyclosporine, Revlimid, Vidaza, Dacogen, ...

Reply
 
Thread Tools Search this Thread
  #1  
Old Sat Oct 23, 2010, 09:46 PM
Greg H Greg H is offline
Member
 
Join Date: Sep 2010
Location: North Carolina
Posts: 660
Under 60 and Have Low Risk MDS? Read this.

[This post is a little unusual in that it's really long. But I've noticed a lot of younger MDSers hanging around here, and I think the theory of the disease and the possible treatments for younger patients that I describe here is important info that gets short shrift in a lot of the usual MDS handbooks you pick up at the oncologist's office. I wrote this for my family, so it's a little elementary for you guys. Hope it's useful.
— Greg]


To hear the guys at NIH tell it, there's a war in my bone marrow.

NIH is the National Institutes of Health, a collection of incredibly smart health care folks who do their investigating mostly at a big campus in Bethesda, MD. The hematology folks there have been methodically working through a theory that some types of MDS begin with an immune reaction gone awry inside the bone marrow. Their research has ranged from test tube work to clinical trials, and understanding the details gets way beyond my college freshman biology and chemistry. But the basics aren't all that tough.

Stem cells with some chromosomal abnormalities -- particularly Trisomy 8 (three copies of chromosome 8, instead of the usual two) -- have on their surfaces proteins that provoke an immune reaction. The immune system sees these proteins as the uniforms of an invading force, and starts multiplying certain T-cell lymphocytes to do battle with the intruders. I happen to have the Trisomy 8 abnormality in about half of my stem cells.

So now we have my T-cells attacking my own Trisomy 8 stem cells. Unfortunately, the Trisomy-8 cells are equipped with other proteins that make them hard to kill -- they're armored! In the heat of battle, with the T-cells piling up and launching futile attacks agains the Trisomy 8s, one or both of two bad things happen: the T-cells start mistakenly attacking some of the normal, garden variety stem cells; or cytokines and other nasty stuff released in the battle between the T-cells and the Trisomy-8 cells start damaging the good stem cells and preventing them from doing their job: making usable red blood cells, white blood cells, and platelets.

]It's just like a real war, where there's "collateral damage," whether from misdirected drone attacks or land mines left lying around for innocent folks to step on. Civilians are wounded and killed.

Even though the T-cells aren't very effective at killing off the Trisomy-8s, they may sometimes damage them, possibly creating more -- and more problematic -- chromosomal abnormalities. That could turn lower-risk MDS into higher-risk MDS over time.

The solution to this problem that the folks at NIH have spent a lot of time exploring involves putting an end to the war, so the collateral damage stops and the civilians can get back to making good blood cells.

They do this not by attacking the Trisomy 8 cells, but by shutting down the immune reaction, using drugs called immunosuppressants. One strategy folks have tried for this is using cyclosporine; but that, on its own, hasn't proven too effective. So one accepted alternative that NIH pioneered is to use a few big doses of ATG, an immunosuppressant derived from horses or rabbits, to knock the immune system flat. That's followed up with cyclosporine, to keep it suppressed. This ATG/cyclosporine regimen is an accepted option for treating certain types of MDS patients and is included in the National Comprehensive Cancer Network treatment guidelines.

The main downside of this strategy is that ATG is a really big gun, basically knocking down all the different kinds of T-cells and leaving the patient seriously open to infections of all sorts. But the NIH folks have evidence that it's really only two specific kinds of T-cells that are involved in this war with the Trisomy 8s. Campath is a drug (derived from rat) that attacks only those T-cells. Folks who take it still wind up with the immune system of an AIDS patient, but mostly have to worry about viruses and one rare type of pneumonia, rather than everything under the sun. Folks participating in NIH's Campath clinical trial take some anti-viral drugs and a special anti-pneumonia treatment to fight off infection for the year or so it takes their T-cells to come back.

When the T-cells do come back, if all goes well, they are more tolerant of the Trisomy 8 cells and the war doesn't crank back up again. Even though the T-cells attacked them, it's not really clear that the Trisomy 8 stem cells are incapable of making good blood. Without the war, they may be able to happily co-exist with their garden variety stem cell brethren, all happily making blood together.

So which MDS patients are likely to have this odd immune system war going on? Different studies of immunosuppressants and MDS have produced different answers, including the following: Younger patients (50s or younger), with Trisomy 8, hypocellular marrow, positive for the HLA-DR15 marker on their white blood cells, not too many transfusions yet, and a couple of other factors. I have all of these characteristics, which means I have a high probability of response to treatment with Campath.

For the NIH trial, the key eligibility factors are age, HLA DR-15 status, and how long you've been getting red blood cell transfusions. The details are on clinicaltrials.gov here. NIH has almost filled its recruitment goal for this trial, but may extend it.

There's a new study of Campath in MDS (and other bone marrow failure diseases) now recruiting at MD Anderson in Houston. That info is here.

[Disclaimer: I have no relationship with Campath or its manufacturer or NIH or MD Anderson other than as an MDSer looking for the best answer to whip this lousy disease!]
__________________
Greg, 59, dx MDS RCMD Int-1 03/10, 8+ & Dup1(q21q31). NIH Campath 11/2010. Non-responder. Tiny telomeres. TERT mutation. Danazol at NIH 12/11. TX independent 7/12. Pancreatitis 4/15. 15% blasts 4/16. DX RAEB-2. Beginning Vidaza to prep for MUD STC. Check out my blog at www.greghankins.com
Reply With Quote
  #2  
Old Sat Oct 23, 2010, 11:32 PM
tytd tytd is offline
Member
 
Join Date: Jul 2009
Location: Southeast, USA
Posts: 132
Campath

Hello Greg,
That was a great explanation of the theory behind immunosuppressive therapy. You sound like a good candidate for Campath. I wonder if patients with hypercellular marrows respond at all or if it just primarily works for those patients with a more aplastic or hypocellular picture. I considered NIH but I am hypercellular without cytogenetic abnormalities or increased blasts so no one knows what I have. Hope you recovered from your post bone marrow experience. Perhaps you had a little bit of bleeding at the site which caused some irritation. Good luck and thanks for the post. Tytd
__________________
possible low to int-1 MDS with predominant thrombocytopenia, mild anemia, dx 7/08, in watch and wait mode
Reply With Quote
  #3  
Old Sun Oct 24, 2010, 02:33 AM
Julianna Julianna is offline
Member
 
Join Date: Feb 2010
Location: Victoria, Australia
Posts: 184
Hey thanks Greg for the war story! Because of my history of AA I've had a lot of explanations over the years, but your really tops the cake!

My Doctor actually said to me that I won't be a candidate for most clinical trials because of the immunosuppression I had for AA, about 14 years ago. I guess that means they doubt it would work anyway. They think mine will turn aggressive eventually. So I guess that's why they are trying for BMT when the time is right.

But who knows... these trials find out some amazing things! Hope you can find something that works fabulous for you.

Thanks again for your awesome story.
__________________
Julie (38yrs); dx AA 1996 & treated w/ATG, cyclosporine & G-CSF; 2010 dx int-1 secondary MDS, low platelets, on prevention antibiotics, fevers of unknown origin, MUD found for BMT when the time is right, which is now! MDS transformed to AML after many infections.
Reply With Quote
  #4  
Old Sun Oct 24, 2010, 03:55 PM
cathybee1 cathybee1 is offline
Member
 
Join Date: Aug 2010
Location: Fort Jones, California
Posts: 399
Greg, that's a great, easy to understand explanation of the research that's going on in this area. Thanks for posting.
__________________
Catherine, wife of Bruce age 75; diagnosed 6/10/11 with macrocytic anemia, neutropenia and mild thrombocytopenia; BMB suggesting emerging MDS. Copper deficient. Currently receiving procrit and neuopogen injections weekly, B12 dermal cream and injections, Transfusions ~ 5 weeks.
Reply With Quote
  #5  
Old Mon Nov 29, 2010, 04:05 PM
Greg H Greg H is offline
Member
 
Join Date: Sep 2010
Location: North Carolina
Posts: 660
New Article on the Mechanics of IST & MDS

Dr. Elaine Sloand and her colleagues at the National Institutes of Health have just published an article in Blood that adds some pieces to the puzzle of why some folks with MDS respond to immunosuppressive therapy [IST] -- that its, ATG & cyclosporine or Campath.

The article is highly technical and well above my pay grade, but its conclusions are pretty interesting and, I think, worth sharing here. (If you want to puzzle it out for yourself, you can find the abstract here, or email me if you'd like a PDF of the full report.)

Dr. Sloand examined MDSers who have the Trisomy 8 chromosomal abnormality and found that they were much more likely than regular folks and somewhat more likely than other MDSers to have a version of the WT1 gene in their Trisomy 8 stem cells. Previous NIH studies have shown that folks with Trisomy 8 are more likely to respond to IST, which is why Dr. Sloand has been focusing on this subset of MDSers.

Dr. Sloand found that these same Trisomy 8 folks have CD4 and CD8 T cell lymphocytes that are programmed to attack the WT1 gene. So WT1 appears to be the spark that sets off the war between T cells and marrow stem cells that I described in an earlier post.

When the researchers added some of those WT1-sensitive CD8 T cells to some perfectly normal bone marrow stem cells, blood production was suppressed. That suggests that T cells wired this particular way can suppress blood production by normal stem cells -- in other words, the T cells aren't just messing with the Trisomy 8 stem cells, they are messing up blood production more generally.

Connecting the dots, folks with Trisomy 8 MDS have a T cell war going on in their bone marrow, in which WT1-sensitive T cells attack Trisomy 8 stem cells carrying the the WT1 gene, and create collateral damage among all the innocent normal stem cells, suppressing overall blood production.

When Dr. Sloand compared the marrow of folks before and after IST, she found that the number of Trisomy 8 stem cells can actually increase after a positive response to immunosuppression -- yet the marrow otherwise returns to normal and blood production improves. That suggests the dysplasia in this kind of myelodysplasia is more the result of the immune attack than poor blood production by the Trisomy 8 stem cells.

It also suggests that immunosuppression can allow the MDS clone to continue to grow unchecked. But Dr. Sloand and her colleagues write that, in a decade of experience using immunosuppression to treat MDS, they have not found any increased conversion to leukemia among folks treated with this therapy.
__________________
Greg, 59, dx MDS RCMD Int-1 03/10, 8+ & Dup1(q21q31). NIH Campath 11/2010. Non-responder. Tiny telomeres. TERT mutation. Danazol at NIH 12/11. TX independent 7/12. Pancreatitis 4/15. 15% blasts 4/16. DX RAEB-2. Beginning Vidaza to prep for MUD STC. Check out my blog at www.greghankins.com
Reply With Quote
  #6  
Old Sun Sep 18, 2011, 02:58 PM
arieschris arieschris is offline
Member
 
Join Date: Sep 2011
Location: CALIFORNIA
Posts: 6
Quote:
Originally Posted by tytd View Post
Hello Greg,
That was a great explanation of the theory behind immunosuppressive therapy. You sound like a good candidate for Campath. I wonder if patients with hypercellular marrows respond at all or if it just primarily works for those patients with a more aplastic or hypocellular picture. I considered NIH but I am hypercellular without cytogenetic abnormalities or increased blasts so no one knows what I have. Hope you recovered from your post bone marrow experience. Perhaps you had a little bit of bleeding at the site which caused some irritation. Good luck and thanks for the post. Tytd
Are you still in watch and wait mode? How are you doing today? I am also in watch and wait mode-just diagnosed.
Reply With Quote
Reply


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -4. The time now is 05:20 AM.


Powered by vBulletin® Version 3.6.7
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
Forum sites may contain non-authoritative and unverified information.
Medical decisions should be made in consultation with qualified medical professionals.
Site contents exclusive of member posts Copyright © 2006-2020 Marrowforums.org